1887
Skip to content
Research Open Access
Like 0

Abstract

BACKGROUND

Numbers of infections (CDI) in England have risen since 2021, but for unclear reasons.

AIM

This study’s objective was to understand factors driving CDI increases, and their relative impact.

METHODS

We conducted a case–control study in England from 2019/20 to 2023/24, with CDI case data linked to hospitalisation episodes. Controls were non-CDI related hospitalisation episodes. A logistic regression model estimated odds ratios (ORs) for primary care prescribing, comorbidities, demographic factors, region and testing rates. To assess temporal changes, the model was fitted to 2019/20 data to predict, from 2020/21 onwards, case numbers, which were compared to observations. The relative contribution of factors to the model performance was evaluated by their stepwise inclusion into it, starting from a baseline considering hospitalisation numbers. Prediction improvements were assessed after each incorporation.

RESULTS

The strongest CDI risk factors were prescriptions (e.g. OR for clindamycin: 5.22; p < 0.001), comorbidities (OR: 1.17; p < 0.001), and age (OR: 1.03; p < 0.001). All ethnicities except White negatively associated with CDIs. Among regions, the North West and Yorkshire and Humber had the highest ORs (1.17 and 1.15 respectively; p < 0.001). Demographic changes and antibiotic use explained 12.6% of the difference between observed cases in 2023/24 and our baseline model whereas including comorbidities and testing rates explained 65.3%.

CONCLUSION

Increases in overall hospital admissions, comorbidities and testing largely explained rising case numbers, which also stemmed from an ageing population, demographic changes and more primary care antibiotic prescribing Nevertheless, these factors did not fully account for observed increases, so further determinants should be sought.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.37.2500888
2026-09-17
2026-11-10
/content/10.2807/1560-7917.ES.2026.31.37.2500888
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/37/eurosurv-31-37-2.html?itemId=/content/10.2807/1560-7917.ES.2026.31.37.2500888&mimeType=html&fmt=ahah

References

  1. Tresman R, Goldenberg SD. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes. J Antimicrob Chemother. 2018;73(10):2851-5.  https://doi.org/10.1093/jac/dky250  PMID: 29982502 
  2. Martin JSH, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206-16.  https://doi.org/10.1038/nrgastro.2016.25  PMID: 26956066 
  3. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164-70.  https://doi.org/10.1016/j.cmi.2014.08.017  PMID: 25658560 
  4. Boven A, Vlieghe E, Engstrand L, Andersson FL, Callens S, Simin J, et al. Clostridioides difficile infection-associated cause-specific and all-cause mortality: a population-based cohort study. Clin Microbiol Infect. 2023;29(11):1424-30.  https://doi.org/10.1016/j.cmi.2023.07.008  PMID: 37473840 
  5. Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P. Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol Mol Biol Rev. 2000;64(3):548-72.  https://doi.org/10.1128/MMBR.64.3.548-572.2000  PMID: 10974126 
  6. Davies K, Lawrence J, Berry C, Davis G, Yu H, Cai B, et al. Risk Factors for Primary Clostridium difficile Infection; Results From the Observational Study of Risk Factors for Clostridium difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Front Public Health. 2020;8:293.  https://doi.org/10.3389/fpubh.2020.00293  PMID: 32766196 
  7. Ghosh S, Antunes A, Rinta-Kokko H, Chaparova E, Lay-Flurrie S, Tricotel A, et al. Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study. Int J Infect Dis. 2024;140:31-8.  https://doi.org/10.1016/j.ijid.2024.01.002  PMID: 38185320 
  8. Armstrong EP, Malone DC, Franic DM, Pham SV, Gratie D, Amin A. Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review. Infect Dis Ther. 2023;12(7):1775-95.  https://doi.org/10.1007/s40121-023-00833-x  PMID: 37395984 
  9. UK Health Security Agency (UKHSA). Increase in Clostridioides difficile infections (CDI): current epidemiology, data and investigations – Technical report. London: UKHSA; 2025. Available from: https://www.gov.uk/government/publications/increase-in-clostridioides-difficile-infections-technical-report/increase-in-clostridioides-difficile-infections-cdi-current-epidemiology-data-and-investigations-technical-report
  10. Department of Health and Social Care. Clean, safe care: Reducing infections and saving lives. London: Department of Health and Social Care; 2008. Available from: https://webarchive.nationalarchives.gov.uk/ukgwa/20130123193013/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081650
  11. Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. , Modernising Medical Microbiology Informatics Group. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17(4):411-21.  https://doi.org/10.1016/S1473-3099(16)30514-X  PMID: 28130063 
  12. GOV.UK. MRSA, MSSA and Gram-negative bacteraemia and CDI: annual report. 2026. [Accessed 17 Mar 2026]. Available from: https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary
  13. GOV.UK. Clostridioides difficile ribotyping network (CDRN) report. 2026. [Accessed 17 Mar 2026]. Available from: https://www.gov.uk/government/publications/clostridium-difficile-ribotyping-network-cdrn-report
  14. Angulo FJ, Furtado M, Gonzalez E, Zhang P, Kelly PH, Moïsi JC. Incidence of public health surveillance-reported Clostridioides difficile infections in thirteen countries worldwide: A narrative review. Anaerobe. 2024;88:102878.  https://doi.org/10.1016/j.anaerobe.2024.102878  PMID: 38909713 
  15. European Centre for Disease Prevention and Control (ECDC). Clostridium difficile infections - annual epidemiological report 2018-2020. Stockholm: ECDC. [Accessed 25 Mar 2026]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER-Clostridium-difficile-2018-2020.pdf
  16. UK Health Security Agency (UKHSA). Mandatory enhanced MRSA, MSSA and Gram-negative bacteraemia, and Clostridioides difficile infection surveillance - Protocol version 4.4. London: UKHSA. [Accessed 12 Nov 2025]. Available from: https://hcaidcs.ukhsa.gov.uk/ContentManagement/LinksAndAnnouncements/HCAIDCS_Mandatory_Surveillance_Protocol_v4.4.pdf
  17. GOV.UK. Quality and methodology information (QMI) for healthcare-associated infections (HCAI) reports. [Accessed 17 Oct 2025]. Available from: https://www.gov.uk/government/statistics/hcai-qmi-report/quality-and-methodology-information-qmi-for-healthcare-associated-infections-hcai-reports
  18. Soong JTY, Gammall J, Liew D, Peden CJ, Bottle A, Bell D, et al. Dr Foster global frailty score: an international retrospective observational study developing and validating a risk prediction model for hospitalised older persons from administrative data sets. BMJ Open. 2019;9(6):e026759.  https://doi.org/10.1136/bmjopen-2018-026759  PMID: 31230009 
  19. R: The R Project for Statistical Computing. [Accessed 12 Mar 2026]. Available from: https://www.r-project.org/
  20. Clindamycin | Drugs | BNF content published by NICE. [Accessed 23 Oct 2025]. Available from: https://bnf.nice.org.uk/drugs/clindamycin/
  21. Cusumano G, Flores GA, Venanzoni R, Angelini P. The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies. Antibiotics (Basel). 2025;14(4):371.  https://doi.org/10.3390/antibiotics14040371  PMID: 40298495 
  22. Spigaglia P. Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Anaerobe. 2022;74:102518.  https://doi.org/10.1016/j.anaerobe.2022.102518  PMID: 35063599 
  23. Voona S, Abdic H, Montgomery R, Clarkson A, Twitchell H, Hills T, et al. Impact of COVID-19 pandemic on prevalence of Clostridioides difficile infection in a UK tertiary centre. Anaerobe. 2022;73:102479.  https://doi.org/10.1016/j.anaerobe.2021.102479  PMID: 34801705 
  24. Ponce-Alonso M, Sáez de la Fuente J, Rincón-Carlavilla A, Moreno-Nunez P, Martínez-García L, Escudero-Sánchez R, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2021;42(4):406-10.  https://doi.org/10.1017/ice.2020.454  PMID: 32895065 
  25. Ray MJ, Furuno JP, Strnad LC, Lofgren ET, McGregor JC. Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2024;45(12):1428-34.  https://doi.org/10.1017/ice.2024.128  PMID: 39429023 
  26. Lastinger LM, Alvarez CR, Kofman A, Konnor RY, Kuhar DT, Nkwata A, et al. Continued increases in the incidence of healthcare-associated infection (HAI) during the second year of the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2023;44(6):997-1001.  https://doi.org/10.1017/ice.2022.116  PMID: 35591782 
  27. Abubakar U, Awaisu A, Khan AH, Alam K. Impact of COVID-19 Pandemic on Healthcare-Associated Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2023;12(11):1600.  https://doi.org/10.3390/antibiotics12111600  PMID: 37998802 
/content/10.2807/1560-7917.ES.2026.31.37.2500888
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error